[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-439834-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-439834-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","nipocalimab-in-the-management-of-generalized-myasthenia-gravis-a-new-targeted-therapeutic-approach","Nipocalimab in the management of generalized myasthenia gravis - a new targeted therapeutic approach","","A letter to the editor discusses generalized myasthenia gravis (gMG) as a chronic antibody-mediated neuromuscular disorder marked by weakness that can progress from mild symptoms to life-threatening involvement of bulbar, limb, neck, ocular, and respiratory muscles. It reviews limitations of conventional therapies, including major adverse effects and persistent dependence on procedures like plasmapheresis. Nipocalimab, an FcRn blocker, is highlighted for reducing pathogenic IgG autoantibodies while sparing IgM/IgA and cell-mediated immunity. Clinical trial trends linking antibody reduction with faster strength and quality-of-life improvements support a targeted, steroid-sparing strategy, balanced against remaining questions on long-term safety, relapse risk, vaccination efficacy, and access.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/nipocalimab-in-the-management-of-generalized-myasthenia-gravis-a-new-targeted-therapeutic-approach/439834/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/nipocalimab-in-the-management-of-generalized-myasthenia-gravis-a-new-targeted-therapeutic-approach/439834.png","ImageObject",300,407,{"name":42,"@type":43},"McQueen","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes generalized myasthenia gravis challenging to treat?","Question",{"text":63,"@type":64},"gMG is driven by pathogenic autoantibodies that impair neuromuscular signaling, and conventional therapies often require chronic use, leading to cumulative toxicity and persistent reliance on invasive options for some patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does nipocalimab target the disease mechanism?",{"text":68,"@type":64},"Nipocalimab binds to FcRn, disrupting IgG recycling and accelerating degradation of IgG subclasses, including anti-AChR and anti-MuSK antibodies.",{"name":70,"@type":61,"acceptedAnswer":71},"What advantages and limitations are noted for nipocalimab?",{"text":72,"@type":64},"The letter emphasizes steroid-sparing benefits and fewer adverse events, with IgM/IgA and cell-mediated immunity spared; limitations include concerns about prolonged IgG suppression, incomplete long-term safety data, relapse and vaccination efficacy questions, and access/cost barriers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},439834,1790817063,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":97,"preview_page_count":4},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Letter to the Editor  \nNipocalimab in the management of generalized myasthenia gravis: a new targeted therapeutic approach  \nMuddassir Khalid, MBBSa ,*, Ehtisham Haider, MBBSb , Afzaal Khan, MBBSc , Noor-Ul-Eman Haider, MBBSd  \nDear Editor,  \nMyasthenia gravis is a chronic autoimmune, antibody-mediated neuromuscular disorder characterized by weakness of skeletal muscle. It often involves bulbar, limb, neck, and respiratory muscles, along with ocular manifestations, due to pathogenic autoantibodies against the acetylcholine receptor (anti-AChR) or muscle-specific kinase (anti-MuSK) . These antibodies impair synaptic signaling at the neuromuscular junction, resulting ina spectrum of clinical features ranging from mild to life-threatening[1]. Conventional therapies include acetylcholinesterase inhibitors, corticosteroids, and broad-spectrum immunosuppressants. While these agents provide clinical benefit, they are associated with significant adverse effects: bradycardia, hypotension, paradoxical muscle weakness, osteoporosis, diabetes, bone marrow suppression, and hepatotoxicity. In addition, many patients remain dependent on invasive procedures, such as plasmapheresis, which cannot be maintained in the long term[2] . Generalized myasthenia gravis (gMG) therefore remains a therapeutic dilemma, with most patients requiring chronic immunosuppression that carries cumulative toxicity[3].  \nTargeted treatments such as complement inhibitors have shown benefit in subsets of patients but fail to adequately address the heterogeneity of antibody subtypes encountered in the clinic[4] . This creates a pressing need for therapeutic strategies that are effective across antibody subtypes, safer, and more sustainable. Nipocalimab (Imaavy), a novel neonatal Fc receptor (FcRn) blocker, represents a promising approach. By binding to FcRn, it disrupts IgG recycling and accelerates degradation of all IgG subclasses, including pathogenic anti-AChR and anti-MuSK antibodies [5] . This reduction in circulating autoantibodies  \naDepartment of Medicine, Nishtar Medical University, Multan, Pakistan,  \nbDepartment of Medicine, Punjab Medical College, Faisalabad, Pakistan, cDepartment of Medicine, Al Nafees Medical College, Islamabad, Pakistan and dDepartment of Medicine, Khyber Medical College, Peshawar, Pakistan Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.  \n*Corresponding author. Address: Department of Medicine, Nishtar Medical University, Multan 60000, Pakistan. Tel.: +[923330333544. E-mail: dr.muddassirkhalid@gmail.com](923330333544. E-mail: dr.muddassirkhalid@gmail.com)[ ](923330333544. E-mail: dr.muddassirkhalid@gmail.com)(M. Khalid).  \nCopyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nAnnals of Medicine & Surgery (2026) 88:1034–1035  \nReceived 4 October 2025; Accepted 11 November 2025  \nPublished online 24 November 2025  \n[http://dx.doi.org/10.1097/MS9.0000000000004390](http://dx.doi.org/10.1097/MS9.0000000000004390)  \nrestores neuromuscular transmission and improves clinical outcomes. Importantly, IgM, IgA, and cell-mediated immunity are spared, minimizing the risk of infections and generalized immunosuppression. Unlike corticosteroids or conventional immunosuppressants, nipocalimab does not cause osteoporosis, diabetes, hypertension, or direct hepatic or renal toxicity[3,5] . Clinical evidence supports these mechanistic advantages. In early trials, patients receiving nipocalimab demonstrated rapid improvement in muscle strength and quality-of-life measures, with onset of benefit observed within weeks. The decline in circulating antibody levels closely paralleled clinical improvement, supporting the causal mechanism[6] . Moreover, nipocalima","cbCaidx0aHyng7Oh","https://ap.wps.com/l/cbCaidx0aHyng7Oh","pdf",166052,"English","# Letter to the Editor\n## Background: gMG and limitations of conventional therapy\n## Rationale for targeted treatment with nipocalimab\n## Clinical evidence and safety considerations\n## Limitations and future directions\n## Conclusion","[{\"question\":\"What makes generalized myasthenia gravis challenging to treat?\",\"answer\":\"gMG is driven by pathogenic autoantibodies that impair neuromuscular signaling, and conventional therapies often require chronic use, leading to cumulative toxicity and persistent reliance on invasive options for some patients.\"},{\"question\":\"How does nipocalimab target the disease mechanism?\",\"answer\":\"Nipocalimab binds to FcRn, disrupting IgG recycling and accelerating degradation of IgG subclasses, including anti-AChR and anti-MuSK antibodies.\"},{\"question\":\"What advantages and limitations are noted for nipocalimab?\",\"answer\":\"The letter emphasizes steroid-sparing benefits and fewer adverse events, with IgM/IgA and cell-mediated immunity spared; limitations include concerns about prolonged IgG suppression, incomplete long-term safety data, relapse and vaccination efficacy questions, and access/cost barriers.\"}]","Nipocalimab in the management of generalized myasthenia gravis - a new targeted therapeutic approach | PDF",1790690360]